Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.

European journal of clinical pharmacology - 1 Jul 2003

Hummers-Pradier Eva, Hess Stephan, Adham Ibrahim M, Papke Thomas, Pieske Burkert, Kochen Michael M

Abstract excerpt

BACKGROUND: In patients on oral anticoagulation with warfarin, genetic variations of the cytochrome P 450-CYP2C9 have recently been associated with very low warfarin requirements. Patients needing low doses had an increased risk for bleeding complications. In Germany, phenprocoumon (having a similar metabolic pathway) is the most commonly employed vitamin K antagonist. Treatment is usually monitored by general...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation

Share to Cross-Sectional Studies

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to Hemorrhage

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 12728288
DOI: 10.1007/s00228-003-0580-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.PMID 12728288Read ↗

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.Semantic proximity Read ↗

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.Semantic proximity Read ↗

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumonSemantic proximity Read ↗

Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing.Semantic proximity Read ↗

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.Semantic proximity Read ↗

CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.Semantic proximity Read ↗

Pharmacogenetics of Oral Anticoagulant TherapySemantic proximity Read ↗

Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.Semantic proximity Read ↗

An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.